
SUPPLEMENTAL MATERIAL

Supplemental Figure 1. Study schema.

Supplemental Table 1. Changes in exploratory and safety outcome measures in those randomized to ferric citrate vs. ferrous sulfate for 12 weeks.

Supplemental Figure. Study schema

STUDY PERIOD



Supplemental Table 1. Changes in exploratory and safety outcome measures in those randomized to ferric citrate vs. ferrous sulfate for 12 weeks.

	Baseline values, mean (SD)		12-week change from baseline, mean estimate (95% CI)			
	Ferrous sulfate	Ferric citrate	Ferrous sulfate	Ferric citrate	Difference	P-value
PTH, pg/ml	135 (81)	129 (69)	1 (-24,25)	-5 (-19,10)	7 (-20,34)	0.62
Phosphorus, mg/dL	4.0 (0.9)	3.7 (0.5)	-0.0 (-0.3,0.2)	-0.1 (-0.4,0.1)	-0.1 (-0.2,0.4)	0.52
ERFE, pg/ml	1.4 (0.4)	0.9 (1.4)	-0.3 (-0.9,0.2)	-0.3 (-1.4,0.8)	0.0 (-1.1,1.1)	0.98
IL-6, pg/ml	2.4 (1.9)	1.7 (1.0)	-0.0 (-0.4,0.4)	1.2 (-0.1,2.5)	1.2 (-0.2, 2.6)	0.08
IFN, pg/ml	33 (67)	14 (7)	-18 (-48,12)	7 (-4,18)	25 (-5,54)	0.10
IL-10, pg/ml	0.4 (0.3)	0.3 (0.3)	0.0 (-0.1,0.1)	0.1 (-0.0,0.2)	0.1 (-0.1,0.3)	0.27
TNF, pg/ml	3.1 (1.0)	2.6 (0.8)	-0.1 (-0.4,0.1)	0.1 (-0.2,0.4)	0.2 (-0.2,0.6)	0.23
IL-22, pg/ml	1.2 (1.2)	0.7 (0.7)	1.2 (-0.5,2.9)	0.1 (-0.4,0.6)	-1.0 (-2.7,0.6)	0.19

Abbreviations: PTH, parathyroid hormone; ERFE, erythroferrone; IL, interleukin; IFN, interferon-γ; TNF, tumor necrosis factor-α